|
Abstract
|
Background The estimated road traffic injury death rate in Myanmar increased rapidly from 15 per per 100,000 pop in 2013 to 20.3 in 2015. This recent death rate is 2nd only to Thailand within the Region. A great change from the 6th rank in 2013.
Description of the problem and activities In 2015, the policy maker in the WHO SEARO being informed of the rapid increase reacted in response to the informtion by reassigning the Regional advisor to Myanmar WHO office and mobilised 16,000 USD for intervention. With the seed money and limited time available, a multisectoral road safety project was initiated by the WHO office and the injury prevention focal point from the MOH with the focus on the Yangon - Nay pyi taw - Mandalay Express highway due to the more public awareness and concerned at the national level.This will serve as a pilot project for a larger scale intervention afterwards.the project has very tensed time limitation to finalise all activties within less than 6 months.The project started with a multisectoral meeting among important stakeholders. This already has drawn the attention of the media was news was disseminated.The frame work of the project is the 5 pillars of the Decade of Action for Road Safety 2011-2020. The major activities of the project are 1) close and regular collaboration with the National road safety committee, the transport and police authority 2) secondary data collection from existing combine data sources 3) road safety data workshop 4) journalist workshop 5) "Black Spot" road signage project 6) training of traffic police trainers on preventing road traffic injuries. 7) workshop on strategy development on road safety in collaboration with the ADB.
Results The activities are ongoing. The output, outcome, impact and lessons learned will be presented in the conference.
Conclusions Myanmar road safety situation 2015 is an urgent issue for the nation.
Abstract from Safety 2016 World Conference, 18-21 September 2016; Tampere, Finland. Copyright © 2016 The author(s), Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Language: en |